お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、B型肝炎ワクチンの世界市場、容量、生産量、収益、価格の概要を紹介します。2019~2023年の歴史的な市場収益/売上データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別にB型肝炎ワクチン市場を分類しています。
本レポートでは世界のB型肝炎ワクチン市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：GSK、NCPC、Merck、Bio Kangtai、Dynavax、AIM Vaccine、KM Biologics、LG Life Sciences、Serum Institute

レポートはB型肝炎ワクチンの主要生産者を調査し、主要地域や国の消費状況も提供します。B型肝炎ワクチンの今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2019年から2030年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    Yeast Derived
    CHO Derived

用途別の市場セグメント：
    Children
    Adult

本レポートの詳細内容
本レポートは、世界のB型肝炎ワクチン市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいてB型肝炎ワクチン市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2019年から2024年まで、そして2030年までの予測として、メーカー別、地域別（地域レベル、国レベル）のB型肝炎ワクチン生産量、成長率、市場シェアを調査している。

二. 消費面では、B型肝炎ワクチンの売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2019年から2024年まで、2030年までの予測。

三.主要メーカーのB型肝炎ワクチン売上高、収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のB型肝炎ワクチン市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本B型肝炎ワクチンのレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：B型肝炎ワクチンのレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2019～2030）
第2章： B型肝炎ワクチンの世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2019～2030）
第3章：世界、地域、国レベルにおけるB型肝炎ワクチンの売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2019～2030）
第4章B型肝炎ワクチンメーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2019～2024）
第5章：B型肝炎ワクチンの各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2019～2030）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2019～2030）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2019～2030）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第12章：B型肝炎ワクチンの主要メーカーの概要を提供し、製品の説明と仕様、B型肝炎ワクチンの売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2019～2024）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：B型肝炎ワクチンの市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people routine immunization results in more than 95% of people being protected.
The global Hepatitis B Vaccines market is projected to grow from US$ 1364 million in 2024 to US$ 1985 million by 2030, at a Compound Annual Growth Rate (CAGR) of 6.5% during the forecast period.
Global key players of Hepatitis B Vaccines include GSK, Dynavax, NCPC, etc. The top three players hold a share about 64%. North America is the largest market for Hepatitis B Vaccines, which has a share about 45%, followed by Asia-Pacific and Europe with share 31% and 17%, separately. In terms of product type, Yeast Derived is the largest segment, occupied for a share of 85%. In terms of application, Adult is the largest field with a share about 64%.
Report Includes
This report presents an overview of global market for Hepatitis B Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Hepatitis B Vaccines, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Hepatitis B Vaccines, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Hepatitis B Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Hepatitis B Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Hepatitis B Vaccines sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GSK, NCPC, Merck, Bio Kangtai, Dynavax, AIM Vaccine, KM Biologics, LG Life Sciences, Serum Institute, etc.

Market Segmentation
By Company
    GSK
    NCPC
    Merck
    Bio Kangtai
    Dynavax
    AIM Vaccine
    KM Biologics
    LG Life Sciences
    Serum Institute

Segment by Type
    Yeast Derived
    CHO Derived

Segment by Application
    Children
    Adult

Segment by region
    US & Canada
        U.S.
        Canada
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        U.K.
        Italy
        Russia

Middle East, Africa, Latin America
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Hepatitis B Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Hepatitis B Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hepatitis B Vaccines sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

List of Tables
 Table 1. Global Hepatitis B Vaccines Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
 Table 2. Major Manufacturers of Yeast Derived
 Table 3. Major Manufacturers of CHO Derived
 Table 4. Global Hepatitis B Vaccines Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
 Table 5. Global Hepatitis B Vaccines Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 6. Global Hepatitis B Vaccines Revenue by Region (2019-2024) & (US$ Million)
 Table 7. Global Hepatitis B Vaccines Revenue by Region (2025-2030) & (US$ Million)
 Table 8. Global Hepatitis B Vaccines Revenue Market Share by Region (2019-2024)
 Table 9. Global Hepatitis B Vaccines Revenue Market Share by Region (2025-2030)
 Table 10. Global Hepatitis B Vaccines Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (M Doses)
 Table 11. Global Hepatitis B Vaccines Sales by Region (2019-2024) & (M Doses)
 Table 12. Global Hepatitis B Vaccines Sales by Region (2025-2030) & (M Doses)
 Table 13. Global Hepatitis B Vaccines Sales Market Share by Region (2019-2024)
 Table 14. Global Hepatitis B Vaccines Sales Market Share by Region (2025-2030)
 Table 15. Global Hepatitis B Vaccines Sales by Manufacturers (2019-2024) & (M Doses)
 Table 16. Global Hepatitis B Vaccines Sales Share by Manufacturers (2019-2024)
 Table 17. Global Hepatitis B Vaccines Revenue by Manufacturers (2019-2024) & (US$ Million)
 Table 18. Global Hepatitis B Vaccines Revenue Market Share by Manufacturers (2019-2024)
 Table 19. Global Key Players of Hepatitis B Vaccines, Industry Ranking, 2021 VS 2022 VS 2023
 Table 20. Hepatitis B Vaccines Price by Manufacturers (2019-2024) & (US$/Dose)
 Table 21. Global Hepatitis B Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 22. Global Hepatitis B Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatitis B Vaccines as of 2023)
 Table 23. Global Key Manufacturers of Hepatitis B Vaccines, Manufacturing Base Distribution and Headquarters
 Table 24. Global Key Manufacturers of Hepatitis B Vaccines, Product Offered and Application
 Table 25. Global Key Manufacturers of Hepatitis B Vaccines, Date of Enter into This Industry
 Table 26. Mergers & Acquisitions, Expansion Plans
 Table 27. Global Hepatitis B Vaccines Sales by Type (2019-2024) & (M Doses)
 Table 28. Global Hepatitis B Vaccines Sales by Type (2025-2030) & (M Doses)
 Table 29. Global Hepatitis B Vaccines Sales Share by Type (2019-2024)
 Table 30. Global Hepatitis B Vaccines Sales Share by Type (2025-2030)
 Table 31. Global Hepatitis B Vaccines Revenue by Type (2019-2024) & (US$ Million)
 Table 32. Global Hepatitis B Vaccines Revenue by Type (2025-2030) & (US$ Million)
 Table 33. Global Hepatitis B Vaccines Revenue Share by Type (2019-2024)
 Table 34. Global Hepatitis B Vaccines Revenue Share by Type (2025-2030)
 Table 35. Hepatitis B Vaccines Price by Type (2019-2024) & (US$/Dose)
 Table 36. Global Hepatitis B Vaccines Price Forecast by Type (2025-2030) & (US$/Dose)
 Table 37. Global Hepatitis B Vaccines Sales by Application (2019-2024) & (M Doses)
 Table 38. Global Hepatitis B Vaccines Sales by Application (2025-2030) & (M Doses)
 Table 39. Global Hepatitis B Vaccines Sales Share by Application (2019-2024)
 Table 40. Global Hepatitis B Vaccines Sales Share by Application (2025-2030)
 Table 41. Global Hepatitis B Vaccines Revenue by Application (2019-2024) & (US$ Million)
 Table 42. Global Hepatitis B Vaccines Revenue by Application (2025-2030) & (US$ Million)
 Table 43. Global Hepatitis B Vaccines Revenue Share by Application (2019-2024)
 Table 44. Global Hepatitis B Vaccines Revenue Share by Application (2025-2030)
 Table 45. Hepatitis B Vaccines Price by Application (2019-2024) & (US$/Dose)
 Table 46. Global Hepatitis B Vaccines Price Forecast by Application (2025-2030) & (US$/Dose)
 Table 47. US & Canada Hepatitis B Vaccines Sales by Type (2019-2024) & (M Doses)
 Table 48. US & Canada Hepatitis B Vaccines Sales by Type (2025-2030) & (M Doses)
 Table 49. US & Canada Hepatitis B Vaccines Revenue by Type (2019-2024) & (US$ Million)
 Table 50. US & Canada Hepatitis B Vaccines Revenue by Type (2025-2030) & (US$ Million)
 Table 51. US & Canada Hepatitis B Vaccines Sales by Application (2019-2024) & (M Doses)
 Table 52. US & Canada Hepatitis B Vaccines Sales by Application (2025-2030) & (M Doses)
 Table 53. US & Canada Hepatitis B Vaccines Revenue by Application (2019-2024) & (US$ Million)
 Table 54. US & Canada Hepatitis B Vaccines Revenue by Application (2025-2030) & (US$ Million)
 Table 55. US & Canada Hepatitis B Vaccines Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 56. US & Canada Hepatitis B Vaccines Revenue by Country (2019-2024) & (US$ Million)
 Table 57. US & Canada Hepatitis B Vaccines Revenue by Country (2025-2030) & (US$ Million)
 Table 58. US & Canada Hepatitis B Vaccines Sales by Country (2019-2024) & (M Doses)
 Table 59. US & Canada Hepatitis B Vaccines Sales by Country (2025-2030) & (M Doses)
 Table 60. Europe Hepatitis B Vaccines Sales by Type (2019-2024) & (M Doses)
 Table 61. Europe Hepatitis B Vaccines Sales by Type (2025-2030) & (M Doses)
 Table 62. Europe Hepatitis B Vaccines Revenue by Type (2019-2024) & (US$ Million)
 Table 63. Europe Hepatitis B Vaccines Revenue by Type (2025-2030) & (US$ Million)
 Table 64. Europe Hepatitis B Vaccines Sales by Application (2019-2024) & (M Doses)
 Table 65. Europe Hepatitis B Vaccines Sales by Application (2025-2030) & (M Doses)
 Table 66. Europe Hepatitis B Vaccines Revenue by Application (2019-2024) & (US$ Million)
 Table 67. Europe Hepatitis B Vaccines Revenue by Application (2025-2030) & (US$ Million)
 Table 68. Europe Hepatitis B Vaccines Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 69. Europe Hepatitis B Vaccines Revenue by Country (2019-2024) & (US$ Million)
 Table 70. Europe Hepatitis B Vaccines Revenue by Country (2025-2030) & (US$ Million)
 Table 71. Europe Hepatitis B Vaccines Sales by Country (2019-2024) & (M Doses)
 Table 72. Europe Hepatitis B Vaccines Sales by Country (2025-2030) & (M Doses)
 Table 73. China Hepatitis B Vaccines Sales by Type (2019-2024) & (M Doses)
 Table 74. China Hepatitis B Vaccines Sales by Type (2025-2030) & (M Doses)
 Table 75. China Hepatitis B Vaccines Revenue by Type (2019-2024) & (US$ Million)
 Table 76. China Hepatitis B Vaccines Revenue by Type (2025-2030) & (US$ Million)
 Table 77. China Hepatitis B Vaccines Sales by Application (2019-2024) & (M Doses)
 Table 78. China Hepatitis B Vaccines Sales by Application (2025-2030) & (M Doses)
 Table 79. China Hepatitis B Vaccines Revenue by Application (2019-2024) & (US$ Million)
 Table 80. China Hepatitis B Vaccines Revenue by Application (2025-2030) & (US$ Million)
 Table 81. Asia Hepatitis B Vaccines Sales by Type (2019-2024) & (M Doses)
 Table 82. Asia Hepatitis B Vaccines Sales by Type (2025-2030) & (M Doses)
 Table 83. Asia Hepatitis B Vaccines Revenue by Type (2019-2024) & (US$ Million)
 Table 84. Asia Hepatitis B Vaccines Revenue by Type (2025-2030) & (US$ Million)
 Table 85. Asia Hepatitis B Vaccines Sales by Application (2019-2024) & (M Doses)
 Table 86. Asia Hepatitis B Vaccines Sales by Application (2025-2030) & (M Doses)
 Table 87. Asia Hepatitis B Vaccines Revenue by Application (2019-2024) & (US$ Million)
 Table 88. Asia Hepatitis B Vaccines Revenue by Application (2025-2030) & (US$ Million)
 Table 89. Asia Hepatitis B Vaccines Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 90. Asia Hepatitis B Vaccines Revenue by Region (2019-2024) & (US$ Million)
 Table 91. Asia Hepatitis B Vaccines Revenue by Region (2025-2030) & (US$ Million)
 Table 92. Asia Hepatitis B Vaccines Sales by Region (2019-2024) & (M Doses)
 Table 93. Asia Hepatitis B Vaccines Sales by Region (2025-2030) & (M Doses)
 Table 94. Middle East, Africa and Latin America Hepatitis B Vaccines Sales by Type (2019-2024) & (M Doses)
 Table 95. Middle East, Africa and Latin America Hepatitis B Vaccines Sales by Type (2025-2030) & (M Doses)
 Table 96. Middle East, Africa and Latin America Hepatitis B Vaccines Revenue by Type (2019-2024) & (US$ Million)
 Table 97. Middle East, Africa and Latin America Hepatitis B Vaccines Revenue by Type (2025-2030) & (US$ Million)
 Table 98. Middle East, Africa and Latin America Hepatitis B Vaccines Sales by Application (2019-2024) & (M Doses)
 Table 99. Middle East, Africa and Latin America Hepatitis B Vaccines Sales by Application (2025-2030) & (M Doses)
 Table 100. Middle East, Africa and Latin America Hepatitis B Vaccines Revenue by Application (2019-2024) & (US$ Million)
 Table 101. Middle East, Africa and Latin America Hepatitis B Vaccines Revenue by Application (2025-2030) & (US$ Million)
 Table 102. Middle East, Africa and Latin America Hepatitis B Vaccines Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 103. Middle East, Africa and Latin America Hepatitis B Vaccines Revenue by Country (2019-2024) & (US$ Million)
 Table 104. Middle East, Africa and Latin America Hepatitis B Vaccines Revenue by Country (2025-2030) & (US$ Million)
 Table 105. Middle East, Africa and Latin America Hepatitis B Vaccines Sales by Country (2019-2024) & (M Doses)
 Table 106. Middle East, Africa and Latin America Hepatitis B Vaccines Sales by Country (2025-2030) & (M Doses)
 Table 107. GSK Company Information
 Table 108. GSK Description and Major Businesses
 Table 109. GSK Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 110. GSK Hepatitis B Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
 Table 111. GSK Recent Developments
 Table 112. NCPC Company Information
 Table 113. NCPC Description and Major Businesses
 Table 114. NCPC Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 115. NCPC Hepatitis B Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
 Table 116. NCPC Recent Developments
 Table 117. Merck Company Information
 Table 118. Merck Description and Major Businesses
 Table 119. Merck Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 120. Merck Hepatitis B Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
 Table 121. Merck Recent Developments
 Table 122. Bio Kangtai Company Information
 Table 123. Bio Kangtai Description and Major Businesses
 Table 124. Bio Kangtai Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 125. Bio Kangtai Hepatitis B Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
 Table 126. Bio Kangtai Recent Developments
 Table 127. Dynavax Company Information
 Table 128. Dynavax Description and Major Businesses
 Table 129. Dynavax Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 130. Dynavax Hepatitis B Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
 Table 131. Dynavax Recent Developments
 Table 132. AIM Vaccine Company Information
 Table 133. AIM Vaccine Description and Major Businesses
 Table 134. AIM Vaccine Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 135. AIM Vaccine Hepatitis B Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
 Table 136. AIM Vaccine Recent Developments
 Table 137. KM Biologics Company Information
 Table 138. KM Biologics Description and Major Businesses
 Table 139. KM Biologics Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 140. KM Biologics Hepatitis B Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
 Table 141. KM Biologics Recent Developments
 Table 142. LG Life Sciences Company Information
 Table 143. LG Life Sciences Description and Major Businesses
 Table 144. LG Life Sciences Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 145. LG Life Sciences Hepatitis B Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
 Table 146. LG Life Sciences Recent Developments
 Table 147. Serum Institute Company Information
 Table 148. Serum Institute Description and Major Businesses
 Table 149. Serum Institute Hepatitis B Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 150. Serum Institute Hepatitis B Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
 Table 151. Serum Institute Recent Developments
 Table 152. Key Raw Materials Lists
 Table 153. Raw Materials Key Suppliers Lists
 Table 154. Hepatitis B Vaccines Distributors List
 Table 155. Hepatitis B Vaccines Customers List
 Table 156. Hepatitis B Vaccines Market Trends
 Table 157. Hepatitis B Vaccines Market Drivers
 Table 158. Hepatitis B Vaccines Market Challenges
 Table 159. Hepatitis B Vaccines Market Restraints
 Table 160. Research Programs/Design for This Report
 Table 161. Key Data Information from Secondary Sources
 Table 162. Key Data Information from Primary Sources


List of Figures
 Figure 1. Hepatitis B Vaccines Product Picture
 Figure 2. Global Hepatitis B Vaccines Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 3. Global Hepatitis B Vaccines Market Share by Type: 2023 & 2030
 Figure 4. Yeast Derived Product Picture
 Figure 5. CHO Derived Product Picture
 Figure 6. Global Hepatitis B Vaccines Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 7. Global Hepatitis B Vaccines Market Share by Application: 2023 & 2030
 Figure 8. Children
 Figure 9. Adult
 Figure 10. Hepatitis B Vaccines Report Years Considered
 Figure 11. Global Hepatitis B Vaccines Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 12. Global Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 13. Global Hepatitis B Vaccines Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Figure 14. Global Hepatitis B Vaccines Revenue Market Share by Region in Percentage: 2023 Versus 2030
 Figure 15. Global Hepatitis B Vaccines Revenue Market Share by Region (2019-2030)
 Figure 16. Global Hepatitis B Vaccines Sales (2019-2030) & (M Doses)
 Figure 17. Global Hepatitis B Vaccines Sales (CAGR) by Region: 2019 VS 2023 VS 2030 (M Doses)
 Figure 18. Global Hepatitis B Vaccines Sales Market Share by Region (2019-2030)
 Figure 19. US & Canada Hepatitis B Vaccines Sales YoY (2019-2030) & (M Doses)
 Figure 20. US & Canada Hepatitis B Vaccines Revenue YoY (2019-2030) & (US$ Million)
 Figure 21. Europe Hepatitis B Vaccines Sales YoY (2019-2030) & (M Doses)
 Figure 22. Europe Hepatitis B Vaccines Revenue YoY (2019-2030) & (US$ Million)
 Figure 23. China Hepatitis B Vaccines Sales YoY (2019-2030) & (M Doses)
 Figure 24. China Hepatitis B Vaccines Revenue YoY (2019-2030) & (US$ Million)
 Figure 25. Asia (excluding China) Hepatitis B Vaccines Sales YoY (2019-2030) & (M Doses)
 Figure 26. Asia (excluding China) Hepatitis B Vaccines Revenue YoY (2019-2030) & (US$ Million)
 Figure 27. Middle East, Africa and Latin America Hepatitis B Vaccines Sales YoY (2019-2030) & (M Doses)
 Figure 28. Middle East, Africa and Latin America Hepatitis B Vaccines Revenue YoY (2019-2030) & (US$ Million)
 Figure 29. Global Hepatitis B Vaccines Sales Share by Manufacturers (2023)
 Figure 30. The Hepatitis B Vaccines Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
 Figure 31. Global Hepatitis B Vaccines Revenue Share by Manufacturers (2023)
 Figure 32. The Top 5 and 10 Largest Manufacturers of Hepatitis B Vaccines in the World: Market Share by Hepatitis B Vaccines Revenue in 2023
 Figure 33. Global Hepatitis B Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 34. Global Hepatitis B Vaccines Sales Market Share by Type (2019-2030)
 Figure 35. Global Hepatitis B Vaccines Revenue Market Share by Type (2019-2030)
 Figure 36. Global Hepatitis B Vaccines Sales Market Share by Application (2019-2030)
 Figure 37. Global Hepatitis B Vaccines Revenue Market Share by Application (2019-2030)
 Figure 38. US & Canada Hepatitis B Vaccines Sales Market Share by Type (2019-2030)
 Figure 39. US & Canada Hepatitis B Vaccines Revenue Market Share by Type (2019-2030)
 Figure 40. US & Canada Hepatitis B Vaccines Sales Market Share by Application (2019-2030)
 Figure 41. US & Canada Hepatitis B Vaccines Revenue Market Share by Application (2019-2030)
 Figure 42. US & Canada Hepatitis B Vaccines Revenue Share by Country (2019-2030)
 Figure 43. US & Canada Hepatitis B Vaccines Sales Share by Country (2019-2030)
 Figure 44. US Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 45. Canada Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 46. Europe Hepatitis B Vaccines Sales Market Share by Type (2019-2030)
 Figure 47. Europe Hepatitis B Vaccines Revenue Market Share by Type (2019-2030)
 Figure 48. Europe Hepatitis B Vaccines Sales Market Share by Application (2019-2030)
 Figure 49. Europe Hepatitis B Vaccines Revenue Market Share by Application (2019-2030)
 Figure 50. Europe Hepatitis B Vaccines Revenue Share by Country (2019-2030)
 Figure 51. Europe Hepatitis B Vaccines Sales Share by Country (2019-2030)
 Figure 52. Germany Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 53. France Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 54. U.K. Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 55. Italy Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 56. Russia Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 57. China Hepatitis B Vaccines Sales Market Share by Type (2019-2030)
 Figure 58. China Hepatitis B Vaccines Revenue Market Share by Type (2019-2030)
 Figure 59. China Hepatitis B Vaccines Sales Market Share by Application (2019-2030)
 Figure 60. China Hepatitis B Vaccines Revenue Market Share by Application (2019-2030)
 Figure 61. Asia Hepatitis B Vaccines Sales Market Share by Type (2019-2030)
 Figure 62. Asia Hepatitis B Vaccines Revenue Market Share by Type (2019-2030)
 Figure 63. Asia Hepatitis B Vaccines Sales Market Share by Application (2019-2030)
 Figure 64. Asia Hepatitis B Vaccines Revenue Market Share by Application (2019-2030)
 Figure 65. Asia Hepatitis B Vaccines Revenue Share by Region (2019-2030)
 Figure 66. Asia Hepatitis B Vaccines Sales Share by Region (2019-2030)
 Figure 67. Japan Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 68. South Korea Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 69. China Taiwan Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 70. Southeast Asia Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 71. India Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 72. Australia Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 73. Middle East, Africa and Latin America Hepatitis B Vaccines Sales Market Share by Type (2019-2030)
 Figure 74. Middle East, Africa and Latin America Hepatitis B Vaccines Revenue Market Share by Type (2019-2030)
 Figure 75. Middle East, Africa and Latin America Hepatitis B Vaccines Sales Market Share by Application (2019-2030)
 Figure 76. Middle East, Africa and Latin America Hepatitis B Vaccines Revenue Market Share by Application (2019-2030)
 Figure 77. Middle East, Africa and Latin America Hepatitis B Vaccines Revenue Share by Country (2019-2030)
 Figure 78. Middle East, Africa and Latin America Hepatitis B Vaccines Sales Share by Country (2019-2030)
 Figure 79. Brazil Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 80. Mexico Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 81. Turkey Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 82. Israel Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 83. GCC Countries Hepatitis B Vaccines Revenue (2019-2030) & (US$ Million)
 Figure 84. Hepatitis B Vaccines Value Chain
 Figure 85. Hepatitis B Vaccines Production Process
 Figure 86. Channels of Distribution (Direct Vs Distribution)
 Figure 87. Bottom-up and Top-down Approaches for This Report
 Figure 88. Data Triangulation
 Figure 89. Key Executives Interviewed